Mirum Pharmaceuticals
Open
$99.14
Prev. Close
$99.12
High
$99.54
Low
$99.04
Market Snapshot
$5.99B
-7.5
-1.85
$336.89M
418
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 369 full-time employees. The company went IPO on 2019-07-18. The firm is focused on the treatment of rare diseases affecting children and adults. The company has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The firm is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 369 full-time employees. The company went IPO on 2019-07-18. The firm is focused on the treatment of rare diseases affecting children and adults. The company has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The firm is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Recently from Cashu
Mirum Pharmaceuticals Strengthens Workforce with Inducement Awards for Rare Disease Commitment
Mirum Pharmaceuticals Enhances Workforce with Inducement Awards Amidst Commitment to Rare Disease Treatment Mirum Pharmaceuticals, Inc., a biopharmaceutical company based in Foster City, California, a…
Mirum Pharmaceuticals Expands Workforce to Boost Rare Disease Treatment Initiatives
Mirum Pharmaceuticals Strengthens Workforce to Enhance Rare Disease Treatment Initiatives Mirum Pharmaceuticals, Inc., a biopharmaceutical company based in Foster City, California, takes a significant…
Mirum Pharmaceuticals Charts Ambitious Growth Strategy for 2024 and Future Expansion
Mirum Pharmaceuticals Sets Ambitious Growth Path for 2024 and Beyond Mirum Pharmaceuticals, Inc., based in Foster City, California, outlines its strategic vision for 2024, forecasting robust growth dr…
Mirum Pharmaceuticals Targets Growth with LIVMARLI and Expanding Rare Disease Pipeline
Mirum Pharmaceuticals Charts a Growth Path for 2024 and Beyond Mirum Pharmaceuticals, Inc., a California-based biotechnology company, outlines a robust growth strategy for 2024, emphasizing significan…